BMY Stock Analysis: Bristol-Myers Squibb | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 127.020m USD | 12M Return: 34.9% | US1101221083 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 655M
EPS Trend: 57.2%
Qual. Beats: 2
Rev. Trend: 92.6%
Qual. Beats: 12
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Bristol-Myers Squibb Company (NYSE: BMY) is a large-cap U.S. biopharmaceutical firm headquartered in Princeton, New Jersey, and founded in 1887. The company operates across the full pharmaceutical value chain, discovering, developing, licensing, manufacturing, marketing, distributing, and selling biopharmaceutical products worldwide.
BMYs product portfolio spans oncology, hematology, immunology, cardiovascular, and neuroscience indications, with key brands including Opdivo and the subcutaneous formulation Opdivo Qvantig for solid tumors, Yervoy and Opdualag for melanoma, Breyanzi for large B-cell lymphoma, Abecma for multiple myeloma, Camzyos for obstructive HCM, Sotyktu for plaque psoriasis, Krazati for KRASG12C-mutated NSCLC, Cobenfy for schizophrenia, and Eliquis for stroke and thromboembolism risk reduction. The company distributes through wholesalers, specialty pharmacies, hospitals, clinics, and government agencies, and maintains a strategic oncology collaboration with Arcus Biosciences.
- Eliquis faces generic competition after patent cliff
- Opdivo and subcutaneous Opdivo Qvantig drive oncology growth
- New launches Cobenfy and Krazati accelerate revenue diversification
- Revlimid and Pomalyst sales erode post loss of exclusivity
- Karuna acquisition expands neuroscience franchise with Cobenfy schizophrenia approval
| Net Income: 9.24b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -5.33 > 1.0 |
| NWC/Revenue: 22.01% < 20% (prev 15.60%; Δ 6.41% < -1%) |
| CFO/TA 0.12 > 3% & CFO 10.7b > Net Income 9.24b |
| Net Debt (34.2b) to EBITDA (15.8b): 2.17 < 3 |
| Current Ratio: 1.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.05b) vs 12m ago 0.74% < -2% |
| Gross Margin: 69.24% > 18% (prev 69.50%; Δ -0.26% > 0.5%) |
| Asset Turnover: 53.90% > 50% (prev 49.58%; Δ 4.32% > 0%) |
| Interest Coverage Ratio: 7.86 > 6 (EBIT TTM 13.0b / Interest Expense TTM 1.65b) |
| A: 0.12 (Total Current Assets 29.8b - Total Current Liabilities 18.8b) / Total Assets 88.8b |
| B: 0.24 (Retained Earnings 21.2b / Total Assets 88.8b) |
| C: 0.14 (EBIT TTM 13.0b / Avg Total Assets 92.8b) |
| D: 0.36 (Book Value of Equity 23.4b / Total Liabilities 65.4b) |
| Altman-Z'' = 2.91 = A |
| DSRI: 0.70 (Receivables 10.6b/14.6b, Revenue 50.0b/48.0b) |
| GMI: 1.00 (GM 69.50% / 69.24%) |
| AQI: 1.03 (AQ_t 0.57 / AQ_t-1 0.56) |
| SGI: 1.04 (Revenue 50.0b / 48.0b) |
| TATA: -0.02 (NI 9.24b - CFO 10.7b) / TA 88.8b) |
| Beneish M = -3.22 (Cap -4..+1) = AA |
As of November 12, 2026, the stock is trading at USD 62.91 with a total of 6,405,983 shares traded. Over the past week, the price has changed by -1.99%, over one month by +9.26%, over three months by -0.08% and over the past year by +34.87%.
Current recommended Stop Loss: 58.90 (which is 6.4% or 2.3 ATR below the current price).
Bristol-Myers Squibb has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold BMY.
- StrongBuy: 6
- Buy: 4
- Hold: 17
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 65.3 | 3.7% |
P/E Trailing = 13.7783
P/E Forward = 9.3897
P/S = 2.5387
P/B = 5.4273
P/EG = 17.0667
Revenue TTM = 50.0b USD
EBIT TTM = 13.0b USD
EBITDA TTM = 15.8b USD
Long Term Debt = 41.8b USD (from longTermDebt, last quarter)
Short Term Debt = 1.25b USD (from shortTermDebt, last quarter)
Debt = 46.7b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.93b
Net Debt = 34.2b USD (calculated: Debt 46.7b - CCE 12.6b)
Enterprise Value = 161b USD (127b + Debt 46.7b - CCE 12.6b)
Interest Coverage Ratio = 7.86 (Ebit TTM 13.0b / Interest Expense TTM 1.65b)
EV/FCF = 17.36x (Enterprise Value 161b / FCF TTM 9.29b)
FCF Yield = 5.76% (FCF TTM 9.29b / Enterprise Value 161b)
FCF Margin = 18.56% (FCF TTM 9.29b / Revenue TTM 50.0b)
Net Margin = 18.47% (Net Income TTM 9.24b / Revenue TTM 50.0b)
Gross Margin = 69.24% ((Revenue TTM 50.0b - Cost of Revenue TTM 15.4b) / Revenue TTM)
Gross Margin QoQ = 68.28% (prev 71.28%)
Tobins Q-Ratio = 1.82 (Enterprise Value 161b / Total Assets 88.8b)
Interest Expense / Debt = 3.54% (Interest Expense 1.65b / Debt 46.7b)
Taxrate = 18.43% (2.09b / 11.3b)
NOPAT = 10.6b (EBIT 13.0b * (1 - 18.43%))
Current Ratio = 1.59 (Total Current Assets 29.8b / Total Current Liabilities 18.8b)
Debt / Equity = 2.00 (Debt 46.7b / totalStockholderEquity, last quarter 23.4b)
Debt / EBITDA = 2.17 (Net Debt 34.2b / EBITDA 15.8b)
Debt / FCF = 3.68 (Net Debt 34.2b / FCF TTM 9.29b)
Total Stockholder Equity = 21.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.96% (Net Income 9.24b / Total Assets 88.8b)
RoE = 43.88% (Net Income TTM 9.24b / Total Stockholder Equity 21.1b)
RoCE = 20.64% (EBIT 13.0b / Capital Employed (Equity 21.1b + L.T.Debt 41.8b))
RoIC = 15.40% (NOPAT 10.6b / Invested Capital 68.8b)
WACC = 5.09% (E(127b)/V(174b) * Re(5.90%) + D(46.7b)/V(174b) * Rd(3.54%) * (1-Tc(0.18)))
Discount Rate = 5.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.12 | Cagr: 0.52%
[DCF] Terminal Value 73.10% ; FCFF base≈11.7b ; Y1≈10.3b ; Y5≈8.28b
[DCF] Fair Price = 48.34 (EV 133b - Net Debt 34.2b = Equity 98.8b / Shares 2.04b; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 57.22 | EPS CAGR: 75.79% | SUE: 1.06 | # QB: 2
Revenue Correlation: 92.60 | Revenue CAGR: 3.15% | SUE: 1.08 | # QB: 12
EPS current Quarter (2027-03-31): EPS=1.51 | Chg30d=+4.78% | Revisions=+29% | Analysts=9
EPS current Year (2026-12-31): EPS=6.44 | Chg30d=-7.29% | Revisions=-72% | GrowthEPS=+4.8% | GrowthRev=+4.2%
EPS next Year (2027-12-31): EPS=6.70 | Chg30d=+1.67% | Revisions=+21% | GrowthEPS=+3.9% | GrowthRev=-2.9%
[Analyst] Revisions Ratio: -22% (up=18, down=29)